- Oncternal is one of the oldest companies in the ROR1 oncology space, a field fraught with recent acquisitions.
- Almost every other player in the ROR1 space has been scooped up by big pharma players, but mostly those in ADCs.
- To understand the different approaches in this niche of oncology, one must separate MABS, ADCs, and CAR-T therapy approaches.
- Regardless of the approach, this niche has deep value, and as an investment, the risks must be weighed against reward.
- The weighing of investment grade risk/reward puts Oncternal clearly in the "Winner's Corner."
For further details see:
Oncternal Therapeutics: Improving Outcomes In 'Standard Of Care' Chemo